MedWatch

Analysts predict possible 2021 guidance upgrade from Demant

Several analysts foresee hearing aid company Demant upgrading guidance for its organic growth or operating result in the coming quarterly report. This might already be reflected in the share price, however.

Photo: Demant / PR

Hearing aid manufacturer Demant may be forthcoming with an upgrade on organic growth or earnings before interest and taxes when the company presents its second-quarter financial statement on Thursday, Aug. 12.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs